EyePoint Inc(EYPT) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 7:58 PM ET (Korea 10/31 08:58)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -3.74 | Insider Own | 6.38% | Shs Outstand | 85.0M | Perf Week | -13.87% |
| Market Cap | 0.03B | Forward P/E | - | EPS next Y | 41.22% | Insider Trans | 0.1% | Shs Float | 80.7M | Perf Month | -89.21% |
| Enterprise Value | -0.13B | PEG | - | EPS next Q | -0.93 | Inst Own | 122.88% | Short Float | 26.34% | Perf Quarter | -97.19% |
| Income | -0.31B | P/S | 10.77 | EPS this Y | -14.57% | Inst Trans | 10.22% | Short Ratio | 2.4 | Perf Half Y | -97.39% |
| Sales | 0.00B | P/B | 0.18 | EPS next 5Y | 27.67% | ROA | -115.86% | Short Interest | 21.26M | Perf YTD | -98.09% |
| Book/sh | 1.96 | P/C | 0.17 | EPS past 3/5Y | -4.94% 2.18% | ROE | -148.7% | 52W High | -98.18% ($19.11) | Perf Year | -97.15% |
| Cash/sh | 2.09 | P/FCF | - | Sales past 3/5Y | -8.83% -1.85% | ROIC | -164.66% | 52W Low | -3.14% ($0.36) | Perf 3Y | -93.9% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -39.78% | Gross Margin | -18.29% | Volatility(W/M) | 10.23% 10.38% | Perf 5Y | -96.96% |
| Dividend TTM | - | EV/Sales | -45.9 | Sales Y/Y TTM | -94.63% | Oper. Margin | -11365.22% | ATR (14) | 0.26 | Perf 10Y | -98.35% |
| Dividend Ex-Date | - | Quick Ratio | 4.46 | EPS Q/Q | -28.45% | Profit Margin | -10994.73% | RSI (14) | 15.65 | Recom | 2.54 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.5 | Sales Q/Q | -90.49% | SMA20 | -80.63% ($1.81) | Beta | 1.71 | Target Price | $12.39 |
| Payout | - | Debt/Eq | 0.13 | Earnings | 2026/8/6 | SMA50 | -89.14% ($3.22) | Rel Volume | 0.69 | Prev Close | $0.38 |
| Employees | 214 | LT Debt/Eq | 0.12 | EPS/Sales Surpr. | -10.82% 14.45% | SMA200 | -96.83% ($11.04) | Avg Volume(3M) | 8.86M | Price | $0.35 |
| IPO | 2005/1/27 | Option/Short | Yes/Yes | Trades | 7778 | Volume | 6,119,175 | Change | -8.32% |
EyePoint Pharmaceuticals (EYPT) is a US clinical-stage biotech focused on treatments for retinal diseases. Leveraging its proprietary bioerodible drug delivery platform, Durasert E, the company is developing therapies that provide sustained, long-term drug release within the eye. Its lead pipeline candidate, Duravyu, is positioned to target wet age-related macular degeneration (wet AMD).
Over the past 1 year, on the lower side
98% below its 1-year high.
Traded less than usual. That is 69% of its average volume.
EYPT has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by -14.6% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $1,077. Peers typically go for $1,010.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -97.0%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
26.3% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #446 of 597 in the industry
Based on market cap of $30M.
FAQ
What kind of company is EYPT?
EYPT belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of EYPT?
The market cap of EYPT is approximately $30M, ranking 5,068 within its sector.
What is the 52-week high and low for EYPT?
EYPT has recorded a 52-week high of $19.11 and a low of $0.36.
